Email Alert RSS
Volume 7 Issue 2
Mar.  2016
Turn off MathJax
Article Contents
Abstract
References
Related Articles
Ye-ye CHEN, Shan-qing LI, Zhen-huan TIAN, Xiao-yun ZHOU, Jia HE, Ye ZHANG, Hong-sheng LIU. Large Cell Neuroendocrine Carcinoma of the Lung:Outcomes after Surgical Resection and Prognostic Factors[J]. Medical Journal of Peking Union Medical College Hospital, 2016, 7(2): 98-103. DOI: 10.3969/j.issn.1674-9081.2016.02.004
Citation: Ye-ye CHEN, Shan-qing LI, Zhen-huan TIAN, Xiao-yun ZHOU, Jia HE, Ye ZHANG, Hong-sheng LIU. Large Cell Neuroendocrine Carcinoma of the Lung:Outcomes after Surgical Resection and Prognostic Factors[J]. Medical Journal of Peking Union Medical College Hospital, 2016, 7(2): 98-103. DOI: 10.3969/j.issn.1674-9081.2016.02.004
shu

Large Cell Neuroendocrine Carcinoma of the Lung:Outcomes after Surgical Resection and Prognostic Factors

  • Department of Thoracic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

More Information
  • Corresponding author:

    LI Shan-qing Tel: 010-69154038, E-mail:pumchlsq@163.com

  • Received Date: June 09, 2015
  • Issue Publish Date: March 29, 2016
    Graphical Abstract
    • Abstract
  •   Objective  To investigate the clinical manifestations, outcomes after surgical management, and prognostic factors of large cell neuroendocrine carcinoma (LCNEC) of the lung.
      Methods  We retrospectively analyzed the data of 35 consecutive cases (29 males, 6 females) of LCNEC of the lung surgically treated and pathologically confirmed in Peking Union Medical College Hospital from January 2000 to January 2014. Their outcomes after receiving surgery-based comprehensive therapy and related prognostic factors were explored.
      Results  The median age of patients was 63(47-77)years and the median duration of disease was 2(1-14)months. No specific symptom was found and preoperative pathological diagnosis was not definitive. Surgical methods included open or thoracoscopic lobectomy and lymph node dissection based on the specific conditions of tumor in each case. Postoperative pathological staging showed stage Ⅰ in 12 cases, stage Ⅱ in 7, stage Ⅲ in 13, and stage Ⅳ in 3. Twenty-three patients received adjuvant therapy. Median survival was 17 months[95% confidence interval (CI):11.4-22.6 months]. The 1-year, 3-year, and 5-year survival rates were 60.6%, 29.0%, and 24.8%, respectively. Tumor stage was significantly related with the overall survival (Cox regression analysis, hazard ration=2.608, 95% CI:1.572-4.327, P=0.000).
      Conclusions  LCNEC is a rare malignancy with tremendous aggressiveness and poor prognosis. Stage of tumor may be the independent risk factor affecting the prognosis. Surgery-based comprehensive therapy could achieve good survival for patients of early stages, especially stages Ⅰ and Ⅱ.
    • FullText(HTML)
    • References (30)
  • [1]
    Barbareschi M, Mariscotti C, Barberis M, et al.Large cell neuroendocrine carcinoma of the lung[J]. Tumori, 1989, 75:583-588. DOI: 10.1177/030089168907500614
    [2]
    Travis WD, Linnoila RI, Tsokos MG, et al. Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases[J]. Am J Surg Pathol, 1991, 15:529-553. DOI: 10.1097/00000478-199106000-00003
    [3]
    Travis WD, Brambilla BE, Müller-Hermelink, et al. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart (WHO Classification of Tumours)[M]. Lyon:IARC Press, 2004:145-247.
    [4]
    Eichhorn F, Dienemann H, Muley T, et al. Predictors of survival after operation among patients with large cell neuroendocrine carcinoma of the lung[J]. Ann Thorac Surg, 2015, 99:983-989. DOI: 10.1016/j.athoracsur.2014.10.015
    [5]
    Iyoda A, Makino T, Koezuka S, et al. Treatment options for patients with large cell neuroendocrine carcinoma of the lung[J]. Gen Thorac Cardiovasc Surg, 2014, 62:351-356. DOI: 10.1007/s11748-014-0379-9
    [6]
    Lababede O, Meziane M, Rice T. Seventh edition of the cancer staging manual and stage grouping of lung cancer:quick reference chart and diagrams[J]. Chest, 2011, 139:183-189. DOI: 10.1378/chest.10-1099
    [7]
    Travis WD, Giroux DJ, Chansky K, et al. The IASLC Lung Cancer Staging Project:proposals for the inclusion of broncho-pulmonary carcinoid tumors in the forthcoming (seventh) edition of the TNM Classification for Lung Cancer[J]. J Thorac Oncol, 2008, 3:1213-1223. DOI: 10.1097/JTO.0b013e31818b06e3
    [8]
    Gridelli C, Rossi A, Airoma G, et al. Treatment of pulmonary neuroendocrine tumours:state of the art and future developments[J]. Cancer Treat Rev, 2013, 39:466-472. DOI: 10.1016/j.ctrv.2012.06.012
    [9]
    Phan AT, Oberg K, Choi J, et al. NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors:well-differentiated neuroendocrine tumors of the thorax (includes lung and thymus)[J]. Pancreas, 2010, 39:784-798. DOI: 10.1097/MPA.0b013e3181ec1380
    [10]
    Travis WD. Advances in neuroendocrine lung tumors[J]. Ann Oncol, 2010, 21 Suppl 7:65-71. http://www.sciencedirect.com/science/article/pii/S0923753419397212
    [11]
    Sakurai H, Asamura H. Large-cell neuroendocrine carcinoma of the lung:surgical management[J]. Thorac Surg Clin, 2014, 24:305-311. DOI: 10.1016/j.thorsurg.2014.05.001
    [12]
    Glisson BS, Moran CA. Large-cell neuroendocrine carcinoma:controversies in diagnosis and treatment[J]. J Natl Compr Canc Netw, 2011, 9:1122-1129. DOI: 10.6004/jnccn.2011.0093
    [13]
    Paci M, Cavazza A, Annessi V, et al. Large cell neuroendocrine carcinoma of the lung:a 10-year clinicopathologic retrospective study[J]. Ann Thorac Surg, 2004, 77:1163-1167. DOI: 10.1016/j.athoracsur.2003.09.070
    [14]
    Asamura H, Kameya T, Matsuno Y, et al. Neuroendocrine neoplasms of the lung:a prognostic spectrum[J]. J Clin Oncol, 2006, 24:70-76. DOI: 10.1200/JCO.2005.04.1202
    [15]
    Grand B, Cazes A, Mordant P, et al. High grade neuroendocrine lung tumors:pathological characteristics, surgical management and prognostic implications[J]. Lung Cancer, 2013, 81:404-409. DOI: 10.1016/j.lungcan.2013.05.008
    [16]
    Veronesi G, Morandi U, Alloisio M, et al. Large cell neuroendocrine carcinoma of the lung:a retrospective analysis of 144 surgical cases[J]. Lung Cancer, 2006, 53:111-115. DOI: 10.1016/j.lungcan.2006.03.007
    [17]
    Sarkaria IS, Iyoda A, Roh MS, et al. Neoadjuvant and adjuvant chemotherapy in resected pulmonary large cell neuroendocrine carcinomas:a single institution experience[J]. Ann Thorac Surg, 2011, 92:1180-1186. DOI: 10.1016/j.athoracsur.2011.05.027
    [18]
    Iyoda A, Hiroshima K, Moriya Y, et al. Postoperative recurrence and the role of adjuvant chemotherapy in patients with pulmonary large-cell neuroendocrine carcinoma[J]. J Thorac Cardiovasc Surg, 2009, 138:446-453. DOI: 10.1016/j.jtcvs.2008.12.037
    [19]
    Shin AR, Shin BK, Choi JA, et al. Large cell neuroendocrine carcinoma of the lung:radiologic and pathologic findings[J]. J Comput Assist Tomogr, 2000, 24:567-573. DOI: 10.1097/00004728-200007000-00010
    [20]
    Akata S, Okada S, Maeda J, et al. Computed tomographic findings of large cell neuroendocrine carcinoma of the lung[J]. Clin Imaging, 2007, 31:379-384. DOI: 10.1016/j.clinimag.2007.04.027
    [21]
    Maleki Z. Diagnostic issues with cytopathologic interpretation of lung neoplasms displaying high-grade basaloid or neuroendocrine morphology[J]. Diagn Cytopathol, 2011, 39:159-167.
    [22]
    Fernandez FG, Battafarano RJ. Large-cell neuroendocrine carcinoma of the lung:an aggressive neuroendocrine lung cancer[J]. Semin Thorac Cardiovasc Surg, 2006, 18:206-210. DOI: 10.1053/j.semtcvs.2006.08.007
    [23]
    Faggiano A, Sabourin JC, Ducreux M, et al. Pulmonary and extrapulmonary poorly differentiated large cell neuroendocrine carcinomas:diagnostic and prognostic features[J]. Cancer, 2007, 110:265-274. DOI: 10.1002/cncr.22791
    [24]
    Takei H, Asamura H, Maeshima A, et al. Large cell neuroendocrine carcinoma of the lung:a clinicopathologic study of eighty-seven cases[J]. J Thorac Cardiovasc Surg, 2002, 124:285-292. DOI: 10.1067/mtc.2002.122523
    [25]
    Battafarano RJ, Fernandez FG, Ritter J, et al. Large cell neuroendocrine carcinoma:an aggressive form of non-small cell lung cancer[J]. J Thorac Cardiovasc Surg, 2005, 130:166-172. DOI: 10.1016/j.jtcvs.2005.02.064
    [26]
    Iyoda A, Travis WD, Sarkaria IS, et al. Expression profiling and identification of potential molecular targets for therapy in pulmonary large-cell neuroendocrine carcinoma[J]. Exp Ther Med, 2011, 2:1041-1045. DOI: 10.3892/etm.2011.343
    [27]
    Isaka M, Nakagawa K, Ohde Y, et al. A clinicopathological study of peripheral, small-sized high-grade neuroendocrine tumours of the lung:differences between small-cell lung carcinoma and large-cell neuroendocrine carcinoma[J]. Eur J Cardiothorac Surg, 2012, 41:841-846. DOI: 10.1093/ejcts/ezr132
    [28]
    Kinoshita T, Yoshida J, Ishii G, et al. The differences of biological behavior based on the clinicopathological data between resectable large-cell neuroendocrine carcinoma and small-cell lung carcinoma[J]. Clin Lung Cancer, 2013, 14:535-540. DOI: 10.1016/j.cllc.2013.04.003
    [29]
    Sun JM, Ahn MJ, Ahn JS, et al. Chemotherapy for pulmonary large cell neuroendocrine carcinoma:similar to that for small cell lung cancer or non-small cell lung cancer?[J]. Lung Cancer, 2012, 77:365-370. DOI: 10.1016/j.lungcan.2012.04.009
    [30]
    Iyoda A, Hiroshima K, Moriya Y, et al. Prospective study of adjuvant chemotherapy for pulmonary large cell neuroendocrine carcinoma[J]. Ann Thorac Surg, 2006, 82:1802-1807. DOI: 10.1016/j.athoracsur.2006.05.109
    • Related Articles

  • Related Articles

    [1]LIU Wenjia, ZHOU Runshi, LI Zunzhu, SU Longxiang, CUI Wenbo, LONG Yun, HE Huaiwu. Applying the Electrical Impedance Tomography to Assess Lung Regional Ventilation Distribution in ICU Patients After Cardiac Surgery and Exploring Its Preliminary Values[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(3): 573-579. DOI: 10.12290/xhyxzz.2023-0626
    [2]LIU Huan, HUANG Xiaoling, DAI Mengying, GUO Jiejie, GAO feng. Clinical Characteristics and Inflammatory Markers of Omicron BA.5.2 Variant Infection in Hospitalized Patients and Their Predictive Role in Disease Prognosis[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(5): 1038-1045. DOI: 10.12290/xhyxzz.2023-0055
    [3]ZHANG Ning, ZHU Wen-ling, LIU Xiao-hong, CHEN Wei, KANG Jun-ren, ZHU Ming-lei, TIAN Ran. Impact of Frailty on the Short-term Prognosis of Hospitalized Elderly Patients with Coronary Heart Disease:A Prospective Cohort Study[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(1): 59-66. DOI: 10.12290/xhyxzz.20190150
    [4]Jian-hua DENG, Han-zhong LI. Clinical Diagnosis and Prognosis of Metastatic Pheochromocytoma and Paraganglioma[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(6): 654-659. DOI: 10.3969/j.issn.1674-9081.2019.06.018
    [5]Jia-qi ZHANG, Lei LIU, Gui-ge WANG, Wen-liang BAI, Shan-qing LI. Clinical Pathological Features and Prognosis of Non-small Cell Lung Cancer with Skip N2 Lymph Node Metastasis[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(3): 272-277. DOI: 10.3969/j.issn.1674-9081.2019.03.015
    [6]Ran ZHOU, Tong-juan ZOU, Wan-hong YIN, Yao QIN, Yi LI, Jing YANG, Yan KANG. nfluence of Mitral Regurgitation on the Prognosis of Patients with Septic Shock[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(5): 426-430. DOI: 10.3969/j.issn.1674-9081.2018.05.010
    [7]Ye-ye CHEN, Zhen-huan TIAN, Xiao-yun ZHOU, Ye ZHANG, Hong-sheng LIU, Shan-qing LI. Diagnostic and Therapeutic Features of Bronchopulmonary Carcinoid[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(4): 352-357. DOI: 10.3969/j.issn.1674-9081.2018.04.012
    [8]Cheng HUANG, Ye-ye CHEN, Shan-qing LI, Xiao-yun ZHOU, Hong-sheng LIU, Li LI, Ying-zhi QIN, Jia HE, Dong-jie MA. Ectopic Adrenocorticotropic Hormone Syndrome Caused by Thoracic Neuroendocrine Tumors: Surgical Treatment and Prognosis Factors[J]. Medical Journal of Peking Union Medical College Hospital, 2017, 8(2-3): 147-153. DOI: 10.3969/j.issn.1674-9081.2017.03.012
    [9]Ye-ye CHEN, Hong-sheng LIU, Shan-qing LI, Cheng HUANG, Li LI, Ying-zhi QIN. Neuroendocrine Tumors of the Thymus: Outcomes after Surgical Resection and Prognostic Factors[J]. Medical Journal of Peking Union Medical College Hospital, 2016, 7(3): 190-194. DOI: 10.3969/j.issn.1674-9081.2016.03.006
    [10]Yu YANG, Quan-zong MAO, Han-zhong LI, Zhi-gang JI, Wei-gang YAN, Shi RONG, Guang-hua LIU, Wei-feng XU, He XIAO, Hui-jun WANG. Clinical Features and Prognosis of Paraneoplastic Syndromes in Renal Malignancies[J]. Medical Journal of Peking Union Medical College Hospital, 2012, 3(2): 195-199. DOI: 10.3969/j.issn.1674-9081.2012.02.014

Catalog

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (259) PDF downloads (8) Cited by()
    Related
    Links: National Health Commission of the People's Republic of China Chinese Academy of Medical Sciences(CAMS) AMLC Check CNKI Database CNKI Term Online Chinese General Practice
    Address：Room 302,Third Floor,Building 7, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China
    Tel：010-69154261/4262
    E - mail：medj@pumch.cn mjpumch@126.com
    Copyright of website：Editorial Office of Medical Journal of Peking Union Medical College Hospital

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return
    x Close Forever Close